News - NTRK fusion - LARVOL VERI

KIT Mutation-NTRK fusion oncogenic driver switch: a novel mechanism of acquired imatinib resistance in GIST. (PubMed, NPJ Precis Oncol)

In vitro modeling demonstrated that EML4::NTRK3 confers imatinib resistance, while sensitizing GIST cells to NTRK inhibitors. This first reported instance of an NTRK fusion as a secondary event in GIST progression underscores the importance of testing for NTRK alterations in tumors that have developed resistance to tyrosine kinase inhibitors to ensure patients are offered all available therapeutic options.

1 day ago

Journal

KIT (KIT proto-oncogene, receptor tyrosine kinase) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • EML4 (EMAP Like 4) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NTRK (Neurotrophic receptor tyrosine kinase) • ANO1 (Anoctamin 1)

KIT mutation • PDGFRA mutation • KIT expression • NTRK fusion

imatinib

Molecular Testing for Intrahepatic Cholangiocarcinoma: What, When, How? (PubMed, J Gastrointest Cancer)

Molecular testing has become an essential component of modern iCCA management. Broad, early, and technically integrated molecular profiling-ideally performed at initial diagnosis and interpreted in an interdisciplinary (molecular) tumor board-is critical to fully realize the potential of precision oncology in BTC.

7 days ago

Review • Journal • MSi-H Biomarker

HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK (Neurotrophic receptor tyrosine kinase)

MSI-H/dMMR • HER-2 amplification • IDH1 mutation • FGFR2 mutation • FGFR2 fusion • IDH mutation + NTRK fusion • NTRK fusion

12d

Precision oncology promise in the management of pancreatic acinar cell carcinoma. (PubMed, Eur J Cancer)

In summary, the potential for personalized cancer therapy is promising in PACC. The integration of molecular diagnostics into clinical care is essential for identifying therapeutic targets and optimizing outcomes; continued research and participation in genomically matched clinical trials are key to advancing treatment paradigms for this rare malignancy.

12 days ago

Review • Journal • BRCA Biomarker • MSi-H Biomarker • PARP Biomarker • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NTRK (Neurotrophic receptor tyrosine kinase)

TP53 mutation • BRAF V600E • MSI-H/dMMR • BRAF V600 • ALK rearrangement • ALK fusion • NTRK fusion

12d

Evaluation of NTRK Fusions Detection Method in Esophageal Squamous Cell Carcinoma and Gastric Adenocarcinoma. (PubMed, Int J Mol Sci)

In silico analyses further confirmed that NTRK fusions are rarely present in esophageal and gastric cancers. IHC screening for TRK protein is recommended to detect NTRK fusions, but this method may include many false-positives cases based on the sequencing analysis.

12 days ago

Journal

NTRK (Neurotrophic receptor tyrosine kinase)

NTRK fusion

13d

DNA And RNA-Based Next-Generation Sequencing For Companion Diagnostic Rearrangement Detection In Solid Tumors. (PubMed, Oncologist)

A higher rate of CDx SV detection-most significantly for NRG1 and NTRK fusions-was observed using concurrent DNA-CGP and RNA-CGP compared to DNA-CGP alone. Our results highlight the complementary nature of these methods. Given the substantial clinical benefit of SV targeted therapies, an integrated DNA/RNA profiling strategy should be part of routine clinical care.

13 days ago

Journal • Next-generation sequencing • Companion diagnostic

BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NRG1 (Neuregulin 1) • NTRK (Neurotrophic receptor tyrosine kinase)

NRG1 fusion • NTRK fusion

17d

An Unusual High-Grade Sarcoma of the Kidney with TPM4::NTRK1 Fusion, CDKN2A/B Deletion, SDHD and NOTCH3 Variants: The First Case Report in Pediatric Population. (PubMed, Fetal Pediatr Pathol)

Based on these molecular findings, the diagnosis was confirmed as an NTRK-rearranged high-grade sarcoma with an unusual histomorphological phenotype. This case highlights novel molecular characteristics of NTRK-rearranged high-grade sarcoma and underscores the critical role of comprehensive molecular profiling in diagnosing challenging cases.

17 days ago

Journal

NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NOTCH3 (Notch Receptor 3) • NTRK (Neurotrophic receptor tyrosine kinase) • SDHD (Succinate Dehydrogenase Complex Subunit D) • TPM4 (Tropomyosin 4)

CDKN2A deletion • NTRK fusion

19d

Design, synthesis and biological evaluation of macrocyclic NTRK heterobifunctional degraders. (PubMed, Bioorg Med Chem Lett)

Unfortunately, resistance mutations have created the need for additional therapies. In this study, we detail the design, synthesis, and evaluation of novel NTRK BiDAC™ degraders containing a macrocyclic, mutant active, NTRK targeting ligand.

19 days ago

Journal

NTRK (Neurotrophic receptor tyrosine kinase)

NTRK fusion

27d

CONNECT1903: A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion (clinicaltrials.gov)

P1, N=15, Recruiting, Nationwide Children's Hospital | Trial completion date: Dec 2025 --> Dec 2036 | Trial primary completion date: Dec 2025 --> Dec 2026

27 days ago

Trial completion date • Trial primary completion date

NTRK (Neurotrophic receptor tyrosine kinase)

NTRK fusion

Vitrakvi (larotrectinib)

27d

Update on pediatric soft tissue sarcomas. (PubMed, Curr Opin Pediatr)

Pediatric STS are rare and biologically heterogeneous. Genomic advances have refined risk stratification and uncovered therapeutic targets; further progress relies on international collaboration and trials.

27 days ago

Review • Journal • PD(L)-1 Biomarker • IO biomarker

TP53 (Tumor protein P53) • FOXO1 (Forkhead box O1) • NTRK (Neurotrophic receptor tyrosine kinase) • MYOD1 (Myogenic Differentiation 1)

TP53 mutation • NTRK positive • NTRK fusion

Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Vitrakvi (larotrectinib) • pazopanib • cyclophosphamide • Tazverik (tazemetostat) • Tecelra (afamitresgene autoleucel) • Navelbine oral (vinorelbine tartrate oral)

29d

Infantile Fibrosarcoma of the Hand: Limb-Sparing Treatment With Modern Targeted Oral Chemotherapy and Conservative Surgical Resection. (PubMed, J Hand Surg Glob Online)

At 2 years of follow-up, the patient remains on lorlatinib therapy without recurrence and demonstrates excellent hand function despite moderate scar contractures. This case highlights the efficacy of neoadjuvant therapy combined with resection in managing infantile fibrosarcoma-like tumors.

29 days ago

Journal

ALK (Anaplastic lymphoma kinase) • NTRK (Neurotrophic receptor tyrosine kinase)

NTRK fusion

Lorbrena (lorlatinib)